Daniel Donohue, MD
Interventional Cardiology · Garden City, NYNPI 1003098542
Payments from drug & device makers
Across 50 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$408
- Medtronic$276
- Abbott$254
- AstraZeneca$114
- E.r. Squibb & Sons, L.L.C.$73
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$51
- plus $91 from 4 others
What the payments were for
- Food & beverage$1,267100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $408 |
| Medtronic(2 entities) | 3 | $276 |
| Abbott | 6 | $254 |
| AstraZeneca | 1 | $114 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $51 |
| Teleflex LLC | 1 | $23 |
| Chiesi USA, Inc. | 1 | $23 |
| Penumbra, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Avalus$175
- MitraClip System$117
- FARXIGA$114
How this compares
$1,267 in reported general payments places this provider in the 10th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $158,532 |
| XareltoRivaroxaban | 37 | $39,476 |
| Repatha SureclickEvolocumab | 12 | $17,367 |
| MultaqDronedarone Hcl | 14 | $14,186 |
| Ezetimibe | 141 | $4,080 |
| Metoprolol Succinate | 237 | $4,069 |
| Atorvastatin Calcium | 316 | $2,993 |
| Rosuvastatin Calcium | 196 | $2,978 |
| Ranolazine ErRanolazine | 12 | $1,704 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 24 | $1,563 |
| Valsartan | 65 | $1,278 |
| Carvedilol | 99 | $973 |
| Amlodipine Besylate | 237 | $946 |
| Amiodarone Hcl | 22 | $902 |
| Losartan Potassium | 80 | $744 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Garden City
- Richard SchwartzGarden City$1.1M
- Martin LeonNew York$13.5M
- David CohenRoslyn$9.8M
- Susheel KodaliNew York$6M
- Mohamed Azeem LatibBronx$4.6M
- Richard ShlofmitzRoslyn$4.5M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.